TidalSense Limited

TidalSense Limited is a venture-backed respiratory technology company founded in 2013 and headquartered in Cambridge, United Kingdom. The company describes its mission as revolutionising population-level outcomes for respiratory patients through pathway transformation, with a vision to transform COPD diagnostic pathways and become a global leader in respiratory diagnostics and care management. Its work is grounded in a novel patented sensor technology embedded within its N-Tidal device, which provides insight into lung physiology through high-accuracy, rapid sampling of carbon dioxide (CO2). Combined with the TidalSense cloud platform and AI technologies, this sensor underpins the company's diagnostic and monitoring medical device solutions. The company's flagship offering is N-Tidal Diagnose, described as a revolutionary, first-of-its-kind rapid, accurate, point-of-care diagnostic solution for COPD, delivered as a fully managed service. According to TidalSense, N-Tidal Diagnose is the first new modality (non-spirometry) AI diagnostic device to be cleared under EU MDR for the diagnosis of COPD, setting a new standard and challenging the status quo. It performs near-real-time geometric analysis of breath waveforms to generate a diagnosis at the point of care within a few minutes. A second solution, N-Tidal Capture, is a remote patient monitoring solution powered by the same platform. TidalSense frames its commercial rationale around the scale and cost of respiratory disease. It notes that COPD and asthma affect nearly 10% of the world's population, with COPD now listed as the third leading cause of death worldwide, and that late and inaccurate diagnosis drives billions in healthcare costs through exacerbations and hospitalisations, many of which are preventable. The company positions its technology as a response to diagnostic pathways that have not kept pace with advances in respiratory care management. TidalSense holds ISO 13485:2016 certification and its N-Tidal Diagnose device is an EU MDR Class 2a medical device. The company states that it is venture-backed and works with clinical research partners and investors/funders. It also emphasises sustainability, aiming to set the standard for sustainable medical device development targeting a Net Zero future and minimising single-use plastics in its technologies. Its stated culture prioritises diversity and inclusion to advance equitable healthcare outcomes.

TidalSense Limited was founded in 2013 and is headquartered in Cambridge, United Kingdom. It describes itself as a venture-backed respiratory technology company with a mission to revolutionise population-level outcomes for respiratory patients through pathway transformation. The company's technological foundation is a novel patented sensor technology embedded within its N-Tidal device, which provides insight into lung physiology through high-accuracy and rapid sampling of CO2. This sensor, combined with the TidalSense cloud platform and AI technologies, enables the company's diagnostic and monitoring medical device solutions. The company's flagship diagnostic solution, N-Tidal Diagnose, is described as the first new modality (non-spirometry) AI diagnostic device to be cleared under EU MDR for the diagnosis of COPD. It performs near-real-time geometric analysis of breath waveforms to generate a diagnosis at the point of care within a few minutes, and is delivered as a fully managed service. A second solution, N-Tidal Capture, is a remote patient monitoring solution powered by the same platform. TidalSense holds ISO 13485:2016 certification and its N-Tidal Diagnose device is an EU MDR Class 2a medical device. The company states that it works with investors and funders as well as clinical research partners, and it emphasises sustainable innovation designed around the needs of health systems and patients, including aiming to set the standard for sustainable medical device development targeting a Net Zero future and minimising single-use plastics. It also states that diversity and inclusion are at the heart of its culture, prioritising representation to advance equitable healthcare outcomes.

• 2013

  TidalSense founded; headquartered in Cambridge, United Kingdom.

• N-Tidal Diagnose cleared under EU MDR as the first new modality (non-spirometry) AI diagnostic device for COPD diagnosis.

• Company holds ISO 13485:2016 certification and EU MDR Class 2a device classification.

A venture-backed respiratory diagnostics and care-management company using patented CO2 sensor technology and AI to transform COPD diagnostic pathways, with EU MDR-cleared, ISO 13485-certified medical devices.

• N-Tidal Diagnose

  A rapid, accurate, point-of-care diagnostic solution for COPD, delivered as a fully managed service; the first new modality (non-spirometry) AI diagnostic device cleared under EU MDR for COPD diagnosis, performing near-real-time geometric analysis of breath waveforms.

• N-Tidal Capture

  A remote patient monitoring solution powered by the N-Tidal platform.

• N-Tidal sensor platform

  Patented sensor technology providing high-accuracy, rapid sampling of CO2 for insight into lung physiology.

1. 1TidalSensetidalsense.com
2. 2About Us | TidalSensetidalsense.com
3. 3TidalSense Limited (United Kingdom) - Wikidatawikidata.org